~~<i id='9CFB547F06'><strike id='9CFB547F06'><tt id='9CFB547F06'><pre id='9CFB547F06'></pre></tt></strike></i>~~

Home» focus» knowledge

knowledge

author：comprehensive 2025-10-06 14:38:35 Page View：4

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to keep neuroscience’s past racism from being its future
Next article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

explore

Psychedelics group wrestles with new pharma identity

OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

Affirmative action in medical school literally saved lives

AdobeThepastseveralmonthshavebeengrimforhealthintheU.S.InDecember,theCentersforDiseaseControlandPrev

United colonoscopy coverage change 'may cost lives,' doctors say

AdobeWhengastroenterologistslearnedinMarchthatUnitedHealthcareplanstobarricademanycolonoscopiesbehin

In Spain, a hospital brews its own CAR

MikeReddyforSTATBARCELONA,Spain—Someofthepatientswaitingintheoncologywardofahospitalhere,withitsgree